Table 2.

All adverse events occurring in ≥ 10% of patients regardless of attribution by initially assigned dose

Adverse event	RO7297089 First assigned dose
	60 mg (n = 3)		180 mg (n = 5)		360 mg (n = 4)		1080 mg (n = 12)		1850 mg (n = 3)		All patients (N = 27)
	Any grade	Grade 3–4	Any grade	Grade 3–4	Any grade	Grade 3–4	Any grade	Grade 3–4	Any grade	Grade 3–4	Any grade	Grade 3–4
Hematologic AE
Anemia	1 (33%)	1 (33%)	3 (60%)	3 (60%)	3 (75%)	1 (25%)	3 (25%)	3 (25%)	0	0	10 (37%)	8 (30%)
Platelet count decreased*	1 (33%)	1 (33%)	3 (60%)	2 (40%)	2 (50%)	2 (50%)	2 (17%)	1 (8%)	0	0	8 (30%)	6 (22%)
Non-hematologic AE
Infusion-related reaction	1 (33%)	0	3 (60%)	0	3 (75%)	0	3 (25%)	0	0	0	10 (37%)	0
Back pain	1 (33%)	0	1 (20%)	0	0	0	4 (33%)	1 (8%)	1 (33%)	0	7 (26%)	1 (4%)
ALT increased	0	0	3 (60%)	1 (20%)	0	0	2 (17%)	0	0	0	5 (19%)	1 (4%)
AST increased	0	0	2 (40%)	1 (20%)	0	0	2 (17%)	0	0	0	4 (15%)	1 (4%)
Diarrhea	1 (33%)	0	1 (20%)	0	0	0	2 (17%)	0	0	0	4 (15%)	0
Fatigue	1 (33%)	0	0	0	1 (25%)	1 (25%)	2 (17%)	0	0	0	4 (15%)	1 (4%)
Arthralgia	0	0	0	0	0	0	3 (25%)	0	0	0	3 (11%)	0
CRP increased	1 (33%)	0	1 (20%)	0	0	0	1 (8%)	0	0	0	3 (11%)	0
Dyspnea	0	0	2 (40%)	0	0	0	1 (8%)	0	0	0	3 (11%)	0
Headache	0	0	0	0	0	0	2 (17%)	0	1 (33%)	0	3 (11%)	0
Nausea	0	0	0	0	0	0	2 (17%)	0	1 (33%)	0	3 (11%)	0
Pyrexia	1 (33%)	0	1 (20%)	0	0	0	1 (8%)	0	0	0	4 (15%)	0

AE adverse event, ALT alanine transaminase, AST aspartate transaminase, CRP C-reactive protein

*Platelet count decreased includes the terms thrombocytopenia and platelet count decreased